History of OGT
Founded in 1995 by Professor Ed Southern, Oxford Gene Technology (OGT) has rapidly become one of the leading providers of genetics research and biomarker solutions to customers worldwide.
| 2013 | OGT releases new CytoSure microarray for cancer research |
| 2013 | OGT granted prostate cancer biomarker licence by the ICR |
| 2012 | OGT initiates strategic expansion with the opening of New York office. |
| 2012 | OGT launches the Genefficiency RNA Sequencing Service |
| 2012 | OGT forms Scientific Advisory Board chaired by Peter Rigby, Emeritus Professor of Developmental Biology at the Institute of Cancer Research. |
| 2012 | OGT awarded €3 million from prestigious EU clinical research grants to detect and characterise pathogenic infection in clinical samples |
| 2012 | CytoSure ISCA +SNP array launched for reliable copy number variation detection combined with accurate identification of loss of heterozygosity (LOH) and uniparental disomy (UPD) |
| 2012 |
OGT releases first in a new line of cancer microarrays |
| 2012 |
OGT signs licensing deal for colorectal cancer biomarkers |
| 2012 |
OGT launches optimised rare disease sequencing and analysis service |
| 2012 |
OGT founder Professor Sir Ed Southern awarded the MRC Millennium Medal |
| 2011 | CytoSure Molecular Testing Arrays and Panels launched to deliver reliable detection of DNA copy number changes for a range of molecular disorders |
| 2011 | Working with OGT, NHS targets genotyping for every cancer patient in the UK |
|
2011 |
CytoSure HT Genomic DNA Labelling Kit launched for faster, high-throughput sample processing |
|
2011 |
CytoSure ISCA Sample Tracking Spike-ins launched for easy identification of sample mix-up |
|
2011 |
Genefficiency Sequencing Services launched offering expert project design and data interpretation |
|
2010 |
CytoSure ISCA UPD array launched — the first ever array combining aCGH probes for enhanced CNV calling with SNP content for detection of uniparental disomy |
|
2010 |
OGT’s Biomarker Discovery team announce panel of biomarkers offering potential for significantly improved detection of prostate cancer |
|
2010 |
OGT’s Genefficiency microarray service awarded Agilent High Throughput Certified Service provider status |
|
2010 |
CytoSure Services launched — a dedicated microarray screening service for cytogenetic samples |
|
2010 |
OGT awarded ISO9001, demonstrating ongoing commitment to providing the highest quality solutions and customer service |
|
2010 |
OGT awarded ISO27001, highlighting commitment to information security and confidentiality |
|
2010 |
CytoSure ISCA arrays launched, providing a standardised, evidence-based array format for cytogenetic analysis |
|
2010 |
OGT's Genefficiency Genomic Services awarded 10,000 sample project investigating the relationship between structural variation and susceptibility to type 1 diabetes |
|
2009 |
Launch of CytoSure Genomic DNA Labelling Kit — optimised for high signal-to-noise ratios |
|
2009 |
OGT Genefficiency Genomic Services complete the world’ largest copy number variation study for the Wellcome Trust Case Control Consortium — 20,000 samples screened in less than 20 weeks |
|
2009 |
OGT acquire Sense Proteomic to enhance expertise in diagnostic biomarkers |
|
2009 |
OGT complement CytoSure portfolio with full automation options from SciGene |
|
2009 |
CytoSure DMD array launched, allowing accurate detection of Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD) |
|
2008 |
OGT microarray service awarded Agilent Certified Service Provider status |
|
2008 |
CytoSure Syndrome Plus v2 and Chromosome X arrays launched |
|
2006 |
OGT launch the CytoSure range of arrays and analysis software dedicated to cytogenetic analysis |
|
2003 |
OGT provides its first complete microarray services |
|
1995 |
Professor Sir Edwin Southern founds Oxford Gene Technology (OGT) |
| 1991 | First licensing of DNA microarray patents |
Find out more
For more information about any OGT product or service, please contact us.